Comments
Biocon has said it will divest its 70 per cent stake in its German arm — Axicorp GmbH following its global alliance with Pfizer for commercialisation of biosimilar insulin and insulin analogs.
While announcing its Q4 and yearly results, the company said “it will divest stake in its German subsidiary Axicorp Gmbh to the existing group of promoter shareholders.’’
In February 2008, Biocon had picked up 70 per cent stake in AxiCorp GmbH for a consideration of €30 million.
Post the stake acquisition, Axicorp became the licensee for Biocon’s biosimilar insulin and glargine in Germany and had the sole responsibility for commercialising these products.
“As a consequence of this divestment, these licence rights revert to Biocon,” the company said in a statement.
The company, however, did not disclose the financial details of the divestment.
The move follows Biocon’s global alliance forged last year with Pfizer to commercialise biosimilar insulin and insulin analogs.
“This divestment is in line with the objectives of the global alliance (with Pfizer) wherein the synergies derived from the global development and investments can be leveraged for the German market as well,” the company said.
Axicorp, during the transition period, will continue to provide services to Biocon related to clinical development of insulin and glargine in Europe, it said.
Meanwhile, the company shares were trading at Rs 374.60 on the Bombay Stock Exchange in the late afternoon trade today, down 2.65 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.